(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
31 March 2011 (31.03.2011)

PCT

(10) International Publication Number
WO 2011/038380 A2

(51) International Patent Classification:
A61K 31/519 (2006.01) *A61K 31/501* (2006.01)

(21) International Application Number:
PCT/US2010/050495

(22) International Filing Date:
28 September 2010 (28.09.2010)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/246,265 28 September 2009 (28.09.2009) US
61/385,738 23 September 2010 (23.09.2010) US

(71) Applicant *(for all designated States except US)*: **GLAXOSMITHKLINE LLC** [US/US]; Glaxosmithkline LLC, One Frankline Plaza, 200 North 16th Street, Philadelphia, PA 19102 (US).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **AUGER, Kurt, R.** [US/US]; 1250 South Collegeville Road, Collegeville, PA 19422 (US). **BACHMAN, Kurtis, Earl** [US/US]; 1250 South Collegeville Road, Collegeville, PA 19426 (US). **GILMER, Tona, M.** [US/US]; Five Moore Drive, Research Triangle Park, NC 27709 (US). **GREGOR, James, G., Jr.** [US/US]; 1250 South Collegeville Road, Collegeville, PA 19426 (US). **GRESHOCK, Joel, David** [US/US]; 1250 South Collegeville Road, Collegeville, PA 19426 (US). **LAQUERRE, Sylvie** [US/US]; 709 Swedeland Road, King Of Prussia, PA 19406 (US). **LIU, Li** [US/US]; 709 Swedeland Road, King Of Prussia, PA 19406 (US). **MORRIS, Shannon, Renae** [US/US]; Five Moore Drive, Research Triangle Park, NC 27709 (US).

(74) Agents: **PENG, Tony, W.** et al.; Glaxosmithkline, Corporate Intellectual Property, UW2220, 709 Swedeland Road, P.O. Box 1539, King Of Prussia, PA 19406-0939 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— *without international search report and to be republished upon receipt of that report (Rule 48.2(g))*

WO 2011/038380 A2

(54) Title: COMBINATION

(57) Abstract: The present invention relates to a method of treating cancer in a mammal and to pharmaceutical combinations useful in such treatment. In particular, the method relates to a novel combination comprising the MEK inhibitor: *N* -{3-[3-cyclopropyl-5-[(2-fluoro-4-iodophenyl)amino]-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydropyrido[4,3-*d*/]pyrimidin-1 (2*H*)-yl]phenyl}acetamide, or a pharmaceutically acceptable salt or solvate thereof, and the PI3 kinase inhibitor: 2,4-difluoro-*N*-{2-(methyloxy)-5-[4-(4-pyridazinyl)-6-quinolinyl]-3-pyridinyl}benzenesulfonamide, or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising the same, andNN